Nanshan——headquarters

Built in 2003, Nanshan site as headquarter of Hybio Group, has been focusing on development and manufacturing of Peptide APIs. We have established national and local platforms for drug peptide research, technology innovation and production here. It has passed GMP inspection of NMPA (CFDA), US FDA, EU AEMPS, Brazil ANVISA and South Korea MFDS, etc, and owns tech and know-how for the widest range of Peptide APIs.  

Pingshan——FDF Production Site

As FDF production center, Pingshan Branch is located in Pingshan New District, Shenzhen, and is listed as a "Major Construction Project for Industrial Revitalization" by the National Development and Reform Commission. It covers an area of 25,000 square meters and a building area of 60,000 square meters. Production lines that represent the international advanced level, including 2 vial lines and 1 cartridge line.

Since it was put into production in 2013, it has passed the following GMP certifications: China NMPA, EU EMA, Brazil ANVISA, Pakistan and Indonesia Authority.

Wuhan——API, OSD, Biopharma Site

Founded in 2014, Hybio Pharmaceutical (Wuhan) Co., Ltd is a subsidiary of Hybio Group, it locates in Huangpi district of Wuhan City with around 200 employees. With a total investment over US$150 million, an overall construction area of 250,000 square meters under cGMP standard, Hybio Wuhan site was completed and put into use in the second half of 2018. The new factory consists of four parts: 

· Peptide APIs site: for both solid phase synthesis (SPS) and liquid phase synthesis (LPS). Total 8 buildings, 2 for SPS, 2 for LPS, 2 for purification and lyophilization, 1 for QC and 1 for storage. The production capacity 500-1,000kg/year. 

· Oral Solid Dosage site: for sustained-release drugs, controlled-release drugs, pellets, orally disintegrating tablet, rapid-release drugs, enteric capsule, etc. Capacity 2.5billion pills of solid drugs annually, 1.2 billion pills of pellet & capsule annually. 

· Buildings of offices, staff dormitory, cultural and sports center, parking lot and other constructions are designed with the most advanced concept to provide great working and living environments for all employees.

· Biopharma site: R&D, manufacturing site. ——under constructing.

Changee——Medical Devices Site

Changee Bio-pharmaceutical Co., Ltd was wholly acquired in 2015 by Hybio group.

The factory covers an area of 117 mu, it is integrated with services of pharmaceuticals, medical devices research and development, production and sales. With "drug production license" and "medical equipment manufacturing license" double permit, the factory owns 67 patented technologies, 171 drugs approval, 9 medical device registration certificates, as well as passed the national small volume injection, freeze-dried powder and solid preparations of the new GMP certification.

Dali – Industrial Hemp Processing (CBD) Center

Hybio Biotechnology (Dali) Co., Ltd was established in June 14, 2019 as an industrial hemp deep processing 

base with total investment over 74 million US dollars. 

Hybio Biotech has gained widely supports from the academic field, local government, and the industry field for 

its innovation in hemp processing. It is one of the few companies that owns hemp processing licenses in China 

and has adopted its pharmaceutical technologies in industrial hemp processing to achieve great quality of CBD 

isolate and CBD full spectrum oil. 

The company's vision is to build a closed loop for industrial hemp planting, processing, drug R&D (for epilepsy, 

depression, pain relief etc.) and international marketing, creating a synergy with the operation of its parent 

company Hybio Pharma.